Johnson & Johnson: Legal Woes Are Detrimental But Not Fatal
Summary: Johnson & Johnson stock has continued to underperform the healthcare sector, worrying JNJ investors.
Summary: Johnson & Johnson stock has continued to underperform the healthcare sector, worrying JNJ investors.
Summary: On April 16, Johnson & Johnson released financial results for the first three months
Summary: Johnson & Johnson (JNJ) is positioned to gain on the upside due to solid
Summary: Pharmaceuticals and medical devices giant Johnson & Johnson will report its first quarter 2024
Summary: Johnson & Johnson’s shares have experienced minimal growth over the past five years, in
Summary: Johnson & Johnson settles a consumer protection lawsuit for $75 million, a significant reduction
Summary: Johnson & Johnson continues to trade in line with historical multiples despite improved financial
Summary: Johnson & Johnson focuses on pharmaceuticals and medical devices after spinning off its consumer-health
Summary: Johnson & Johnson is a multinational corporation in the healthcare and pharmaceutical sectors, showing
Summary: Johnson & Johnson reported strong Q4 FY23 results and reaffirmed guidance for FY24, exceeding